Unable to display view head.php file not found.
 
American Journal of Medicine
 

Eikelboom - Evidence from the Randomized Trials - Figure 13
RECOVER I: Bleeding

What about bleeding?  There was no significant difference in major bleeding between warfarin and dabigatran in RE-COVER I, but when we added all kinds of bleeds together, dabigatran substantially reduced the risk by about one-third (Figure 13).[7]  So RE-COVER I showed us that in patients with VTE treated initially with standard parenteral treatment, dabigatran was as effective and somewhat safer than warfarin when continued out to 6 months.

RE-COVER II has not yet been published, but this was a similarly designed trial included a somewhat broader spectrum of patients and produced similar results.   Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000. 

References

[7] Schulman S, Kearon C, Kakkar AK, et al; for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352. Eikelboom - figure 11, figure 12, figure 13

Unable to display view foot.php file not found.